145 related articles for article (PubMed ID: 12100132)
21. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
Nishida T; Murayama T; Hirai H; Okamoto S; Sao H; Hara M; Kanamori H; Atsuta Y; Matsuo K; Morishima Y; Kodera Y
Int J Hematol; 2009 Jan; 89(1):98-105. PubMed ID: 19052693
[TBL] [Abstract][Full Text] [Related]
23. [A clinical study of 19 cases of unrelated heterogenic bone marrow transplantation].
Xu L; Huang X; Ren H; Zhang Y; Guo N; Lu D
Zhonghua Nei Ke Za Zhi; 2002 Apr; 41(4):256-8. PubMed ID: 12133439
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.
Phillips GL; Barnett MJ; Brain MC; Chan KW; Huebsch LB; Klingemann HG; Meharchand J; Reece DE; Rybka WB; Shepherd JD
Bone Marrow Transplant; 1991 Dec; 8(6):477-87. PubMed ID: 1790428
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
26. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.
Morton AJ; Gooley T; Hansen JA; Appelbaum FR; Bruemmer B; Bjerke JW; Clift R; Martin PJ; Petersdorf EW; Sanders JE; Storb R; Sullivan KM; Woolfrey A; Anasetti C
Blood; 1998 Jul; 92(2):394-401. PubMed ID: 9657736
[TBL] [Abstract][Full Text] [Related]
27. Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K; Dodds A; Concannon A; Milliken S
Aust N Z J Med; 1996 Feb; 26(1):54-8. PubMed ID: 8775529
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
Gratwohl A; Hermans J; Niederwieser D; Frassoni F; Arcese W; Gahrton G; Bandini G; Carreras E; Vernant JP; Bosi A
Bone Marrow Transplant; 1993 Nov; 12(5):509-16. PubMed ID: 8298562
[TBL] [Abstract][Full Text] [Related]
29. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.
Castro-Malaspina H; Harris RE; Gajewski J; Ramsay N; Collins R; Dharan B; King R; Deeg HJ
Blood; 2002 Mar; 99(6):1943-51. PubMed ID: 11877264
[TBL] [Abstract][Full Text] [Related]
30. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
31. HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.
Clark RE; Hermans J; Madrigal A; Nachbaur D; Kropshofer G; Gratwohl A; Apperley J; Niederwieser D;
Br J Haematol; 2001 Jul; 114(1):36-41. PubMed ID: 11472342
[TBL] [Abstract][Full Text] [Related]
32. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
33. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A
Leuk Lymphoma; 1996 Dec; 24(1-2):71-9. PubMed ID: 9049963
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
Kolb HJ; Schattenberg A; Goldman JM; Hertenstein B; Jacobsen N; Arcese W; Ljungman P; Ferrant A; Verdonck L; Niederwieser D; van Rhee F; Mittermueller J; de Witte T; Holler E; Ansari H;
Blood; 1995 Sep; 86(5):2041-50. PubMed ID: 7655033
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
Bishop MR; Henslee-Downey PJ; Anderson JR; Romond EH; Marciniak E; Yankey R; Reeves M; Thompson JS
Bone Marrow Transplant; 1996 Oct; 18(4):747-53. PubMed ID: 8899190
[TBL] [Abstract][Full Text] [Related]
36. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children.
Gamis AS; Haake R; McGlave P; Ramsay NK
J Clin Oncol; 1993 May; 11(5):834-8. PubMed ID: 8487047
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.
Morishima Y; Sasazuki T; Inoko H; Juji T; Akaza T; Yamamoto K; Ishikawa Y; Kato S; Sao H; Sakamaki H; Kawa K; Hamajima N; Asano S; Kodera Y
Blood; 2002 Jun; 99(11):4200-6. PubMed ID: 12010826
[TBL] [Abstract][Full Text] [Related]
38. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
39. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
[TBL] [Abstract][Full Text] [Related]
40. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor.
Balduini CL; Frassoni F; Noris P; Klersy C; Iannone AM; Bacigalupo A; Giorgiani G; Di Pumpo M; Locatelli F
Br J Haematol; 2001 Sep; 114(4):951-3. PubMed ID: 11564091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
